Streetbeat News

Stock Prices

BYDDY

NIO

TSLA

NIO and BYD have received approval from Chinese regulators to test their automated driving technology on public roads. This approval marks the first instance of Chinese authorities approving testing for level 3 and level 4 automated driving technologies. Tesla is also preparing to register its 'Full Self-Driving' software in China, highlighting the competitive race in the autonomous driving sector.

Portfolio Pulse from Benzinga Neuro

June 05, 2024 | 1:04 pm

EL

Estee Lauder is expected to extend the tenure of its longtime CEO despite the company's recent struggles, according to sources cited by the Wall Street Journal.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:04 pm

BYD

CZR

LVS

MGM

WYNN

Las Vegas tourism is booming with increased overnight stays, but the gambling sector shows mixed results. Caesars Entertainment reported losses, while MGM Resorts, Las Vegas Sands, and Wynn Resorts saw revenue growth. Boyd Gaming also faced challenges.

Portfolio Pulse from Anthony Noto

June 05, 2024 | 1:04 pm

OLLI

Ollie's Bargain Outlet Holdings Inc (NASDAQ:OLLI) reported strong Q1 FY24 earnings, surpassing analyst expectations and raising its financial outlook. The company saw significant growth in sales, gross profit, and operating income, and increased its FY24 adjusted EPS and sales outlook. Executive changes were also announced, with Eric van der Valk promoted to President and future CEO, and Chris Zender appointed as Executive Vice President and COO.

Portfolio Pulse from Shivani Kumaresan

June 05, 2024 | 1:02 pm

ABBV

AbbVie has initiated the treatment of the first patient with its investigational drug ABBV-383 in the Phase 3 CERVINO study for relapsed/refractory multiple myeloma. The study will compare the efficacy, safety, and tolerability of ABBV-383 monotherapy against standard available therapies in patients who have undergone at least two prior treatments.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:02 pm

MED

MEDIFAST shares are trading lower after DA Davidson downgraded the stock from Neutral to Underperform and lowered its price target from $25 to $17.5.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:02 pm

AMGN

Amgen announced positive Phase 3 trial results for UPLIZNA, showing an 87% reduction in IgG4-RD flares. This is the first randomized, placebo-controlled trial to demonstrate benefit in IgG4-RD, with all primary and key secondary endpoints met.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:01 pm

VLCN

Volcon shares are trading lower after the company announced a 1-for-100 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:01 pm

SAM

Boston Beer Co (NYSE:SAM) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target to $309.0. Analysts have varied in their recommendations, with some raising and others lowering their price targets. The company's financials show positive revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 1:00 pm

CNSP

Trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:55 pm